Clinical characteristics of patients selected for proteome comparison
| No. . | Age, y . | Histology . | Ann Arbor stage . | B symptoms . | Treatment . | Outcome . |
|---|---|---|---|---|---|---|
| 1 | 21 | MC | III | absent | ABVD | FR |
| 2 | 24 | NS | II | present | ABVD/COPP + RT | FR |
| 3 | 24 | NS | IV | present | ABVD/COPP | FR |
| 4 | 26 | NS | II | present | ABVD/COPP + RT | FR |
| 5 | 35 | NS | III | absent | ABVD + RT | FR |
| 6 | 20 | NS | III | present | ABVD/COPP + RT | FR |
| 7 | 25 | NS | III | present | ABVD/COPP + RT | FR |
| 8 | 51 | cHL-NOS | I | present | ABVD/COPP + RT | UR |
| 9 | 41 | NS | IV | present | ABVD/COPP + RT | UR |
| 10 | 14 | NS | III | present | ABVD/COPP | UR |
| 11 | 21 | NS | II | present | ABVD/COPP | UR |
| 12 | 27 | NS | II | present | ABVD/COPP | UR |
| 13 | 33 | NS | IV | present | ABVD | UR |
| 14 | 23 | NS | III | present | ABVD/COPP + RT | UR |
| No. . | Age, y . | Histology . | Ann Arbor stage . | B symptoms . | Treatment . | Outcome . |
|---|---|---|---|---|---|---|
| 1 | 21 | MC | III | absent | ABVD | FR |
| 2 | 24 | NS | II | present | ABVD/COPP + RT | FR |
| 3 | 24 | NS | IV | present | ABVD/COPP | FR |
| 4 | 26 | NS | II | present | ABVD/COPP + RT | FR |
| 5 | 35 | NS | III | absent | ABVD + RT | FR |
| 6 | 20 | NS | III | present | ABVD/COPP + RT | FR |
| 7 | 25 | NS | III | present | ABVD/COPP + RT | FR |
| 8 | 51 | cHL-NOS | I | present | ABVD/COPP + RT | UR |
| 9 | 41 | NS | IV | present | ABVD/COPP + RT | UR |
| 10 | 14 | NS | III | present | ABVD/COPP | UR |
| 11 | 21 | NS | II | present | ABVD/COPP | UR |
| 12 | 27 | NS | II | present | ABVD/COPP | UR |
| 13 | 33 | NS | IV | present | ABVD | UR |
| 14 | 23 | NS | III | present | ABVD/COPP + RT | UR |
FR indicates favorable response; UR, unfavorable response; MC, mixed cellularity; NS, Nodular sclerosis; NOS, not otherwise specified; and RT, radiotherapy.